Table 1.
Patient characteristics (N = 80)
| characteristic | No. of patients | % |
|---|---|---|
| Age(yrs) | ||
| Median | 54.0 | |
| Range | 26.0-79.0 | |
| Sex | ||
| Male | 49 | 61.3 |
| Female | 31 | 38.7 |
| ECOG performance status | ||
| 0 | 36 | 45.0 |
| 1 | 42 | 52.5 |
| 2 | 2 | 2.5 |
| Primary sites | ||
| Cardia | 21 | 26.3 |
| Body | 18 | 22.5 |
| Antrum/pylorus | 41 | 51.2 |
| Metastatic sites | ||
| Liver | 26 | 32.5 |
| Lung | 21 | 26.3 |
| Peritoneum | 19 | 23.8 |
| Others | 14 | 17.4 |
| Pathologic differentiation N0 | ||
| G1 | 2 | 2.5 |
| G2 | 26 | 32.5 |
| G3 | 52 | 65.0 |
| Treatment Response (1st line) | ||
| CR | 2 | 2.5 |
| PR | 36 | 45.0 |
| SD | 24 | 30.0 |
| PD | 18 | 22.5 |
| 2nd-line chemotherary regimen | ||
| BSC | 57 | 71.3 |
| FOLFIRI | 6 | 7.5 |
| XELIRI | 8 | 10.0 |
| DX | 6 | 7.5 |
| TP | 3 | 3.7 |
CR, complete response; PR, partial response; SD, stable disease; PD, progression disease;
BSC, best supportive care; FOLFIRI, 5-fluracil plus leucovorin plus irinotecan; XELIRI, capecitabine plus irinotecan; DX, docitaxel plus capecitabine; TP, paclitaxel plus cisplatin.